MGMT and glioblastoma: Another phase III randomized CheckMate 548 study in patients with newly diagnosed glioblastoma with methylated or indeterminate MGMT promoter demonstrates that nivolumab in combination with radiotherapy and temozolomide does not improve the progression-free survival and overall survival compared with the standard treatment (radiotherapy plus temozolomide) [325].